Impact of Adding Quercetin or Alpha Lipoic Acid as an Adjuvant Therapy on Clinical and Biochemical Outcomes in a Sample of Iraqi PCOS Patients

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• • Newly diagnosed patients should be at reproductive aged from 18-40 years.

‣ Patients diagnosed with presence of micro polycystic ovaries at ultrasound.

⁃ Oligomenorrhea with inter-menstrual intervals longer than 35 days.

⁃ Clinical or biochemical signs of hyperandrogenism (acne, hirsutism).

⁃ Normal PRL levels.

Locations
Other Locations
Iraq
Mustansiriyah University/ College of Pharmacy
RECRUITING
Baghdad
Contact Information
Primary
Mohammed Mahmood Mohammed, professor
pharm.drmhdclinical@uomustansiriyah.edu.iq
7816871131
Time Frame
Start Date: 2025-09-20
Estimated Completion Date: 2026-05-01
Participants
Target number of participants: 150
Treatments
Experimental: Quercetin group
patients assigned to be treated with metformin 500 mg plus a daily dose of Quercetin 500 mg capsule after meal for three months period.
Experimental: Alpha lipoic acid group
patients assigned to be treated with metformin 500 mg plus a daily dose of Alpha lipoic acid 600mg SR capsule after meal for three months period.
Active_comparator: Control group
patients assigned to be treated with metformin 500 mg daily
Sponsors
Leads: Al-Mustansiriyah University

This content was sourced from clinicaltrials.gov